Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1004805 | Other Identifier | OHSU InfoEd | |
| 3986 | Other Identifier | OCTRI |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Portland VA Medical Center | FED |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Addiction to methamphetamine is a serious health problem. There are no medications that a doctor can give someone to help them stop using methamphetamine. Entacapone (Comtan©) is a medication that could help people addicted to methamphetamine.
This study will see how entacapone works in healthy people who are given methamphetamine. We think that the study drug will be well tolerated, and that it will prevent some of the effects of methamphetamine that make it so addictive. We also want to see how differences in people's genes may cause differences in the ways the study drug and methamphetamine work for them.
The study has six total visits. The first visit is for screening. Tests and procedures will make sure it is safe for subjects to participate.
The second visit is a familiarization day. Subjects will receive methamphetamine, but no entacapone. This is done to make sure they can tolerate the drug and recognize its effects before being given a second drug on the same day. Subjects will take surveys and computer tests to see how the medications change mood, thinking, and liking the drug.
The final four visits are the actual study days. Subjects will be randomly assigned (like the flip of a coin) to the different ways to get either 1) study medication or placebo (placebo contains no active study medication) and then 2) methamphetamine or placebo. Subjects will be in all four groups during the study, which means that each day a subject will get a different group.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo followed by Placebo | Placebo Comparator | Subjects will receive placebo, then one hour later, placebo |
|
| Placebo followed by Methamphetamine | Experimental | Subjects will receive placebo, then one hour later, methamphetamine |
|
| Entacapone followed by Placebo | Experimental | Subjects will receive entacapone, then one hour later, placebo |
|
| Entacapone followed by Methamphetamine | Experimental | Subjects will receive entacapone, then one hour later, methamphetamine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Entacapone | Drug | Entacapone 200 mg oral dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| Effect of Entacapone on Methamphetamine-induced Mood | Profile of Mood States is a 65 item questionnaire using a Likert rating scale to assess transient, distinct moods. The questionnaire contains 65 words/statements that describe feelings people have. The test requires you to indicate for each word or statement how you have been feeling in the past week including today. A Total Mood Disturbance score is calculated by adding scores for Tension, Depression, Anger, Fatigue and Confusion and then subtracting the Vigour score. The Total Mood Disturbance scale ranges from -32 to 200 with lower scores indicative of people with more stable mood profiles. | Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint. |
| Effect of Entacapone on Subjective Effects of Methamphetamine | The subjective effects of the study drug were evaluated with the Addiction Research Center Inventory (ARCI-49), a 49 item questionnaire consisting of true/false items. True items receive a score of 1 if answer is 'True', false items receive a score of 1 if answer is 'False'. No points are given when answer is opposite to scoring direction. There are 5 subscales: Morphine Benzedrine group scale to measure euphoria (range: 0-16 with higher numbers indicating more euphoria), A Lysergic Acid Diethylamide group scale to estimate dysphoria and agitation (range: 0-14 with higher scores indicating more dysphoria), a Pentobarbital Chlorpromazine Alcohol group scale to measure sedation (range: 0-15 with higher scores indicating more sedation), and a Benzedrine group scale and an Amphetamine Scale to assess stimulant effects (range: 0-13 and 0-11, respectively, with higher scores indicating higher stimulant effects) . | Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint. |
| Effect of Entacapone on Methamphetamine-induced Stimulation | The Global Rating of Stimulation is a 1-item question "I feel light-headed, restless, or speeded-up" in which the participant is asked to circle one answer on a scale from 0-4, 0 is 'normal', 1 is 'slightly', 2 is 'moderately', 3 is 'very much', and 4 is 'extremely'. Whichever number they circled is their reported score. A higher score is indicative of a greater stimulating effect. |
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive Function | Two computer tests were administered to measure how each medication intervention effects cognitive functioning. The tests administered included the Rapid Visual Information Processing Task (RVIPT), a 6 minute test of sustained attention in which participants are requested to detect target sequences of digits and the Digit Symbol Substitution Task (DSST), a 2 minute test of psychomotor speed and sustained attention consisting of digit-symbol pairs followed by a list of digits where the subject identifies the symbol that corresponds to each digit as fast as possible. The number of correct responses within the allowed time is measured. Higher scores on both tasks indicate better performance. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jonathan C Fellers, MD | Oregon Health and Science University | Principal Investigator |
| William F Hoffman, MD, PhD | VA Portland Healthcare System | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oregon Health & Science University | Portland | Oregon | 97239 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
51 subjects failed the pre-screen primarily due to history of substance use disorder, time commitment conflicts, or unwilling to take methamphetamine. 14 of 29 subjects completed first randomization. Of the 29, 6 declined to participate, 4 did not meet inclusion criteria, 1 was excluded due to an adverse event, and 6 dropped out.
Study staff screened 80 subjects over the phone between June 2014 to June 2016 at a clinical hospital in Portland, OR.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | All Subjects | Subjects will get either entacapone or placebo, then one hour later, either methamphetamine or placebo. Placebo: capsules compounded to be of similar appearance to the active drugs Entacapone: Entacapone 200 mg oral dose Methamphetamine: Methamphetamine 20 mg oral dose The research pharmacy will assign randomization; they have no contact with the subjects or clinical staff involved in direct subject care so this medication combination could occur at any of the 4 randomization visits. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Open-Label Methamphetamine |
|
| |||||||||||||||||||||
| First Intervention |
| ||||||||||||||||||||||
| Second Intervention |
| ||||||||||||||||||||||
| Third Intervention |
| ||||||||||||||||||||||
| Fourth Intervention |
|
Baseline measurements were taken during each randomization visit before participant received any drug treatment. Baseline measurements were then averaged over the 4 randomization visits.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Participants | Participants who completed all four study arms including:
|
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Effect of Entacapone on Methamphetamine-induced Mood | Profile of Mood States is a 65 item questionnaire using a Likert rating scale to assess transient, distinct moods. The questionnaire contains 65 words/statements that describe feelings people have. The test requires you to indicate for each word or statement how you have been feeling in the past week including today. A Total Mood Disturbance score is calculated by adding scores for Tension, Depression, Anger, Fatigue and Confusion and then subtracting the Vigour score. The Total Mood Disturbance scale ranges from -32 to 200 with lower scores indicative of people with more stable mood profiles. | The analysis population includes only the 12 subjects that completed each intervention of the study. | Posted | Mean | Standard Deviation | units on a scale | Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint. |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Open-label Methamphetamine | Subject will receive one dose of open-label methamphetamine 20 mg oral dose on their second visit, the familiarization visit. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Tachycardia | Cardiac disorders | Systematic Assessment | One subject's blood pressure reached 180/100 after ingesting Methamphetamine 20 mg pill but was in the 160s/90s for two hours before normalizing. This subject was removed from the study after this incident. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. William Hoffman | Veterans Affairs Portland Healthcare System | 503-220-8262 | 56491 | hoffmanw@ohsu.edu |
Not provided
| ID | Term |
|---|---|
| C071192 | entacapone |
| D008694 | Methamphetamine |
| ID | Term |
|---|---|
| D000662 | Amphetamines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D000588 | Amines |
| D009930 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Methamphetamine | Drug | Methamphetamine 20 mg oral dose |
|
|
| Placebo | Drug | capsules compounded to be of similar appearance to the active drugs |
|
| Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint. |
| Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint. |
| Received Entacapone-Placebo |
|
| Received Entacapone-Meth |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Received Entacapone-Placebo |
|
| Received Entacapone-Meth |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| Received Entacapone-Placebo |
|
| Received Entacapone-Meth |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| Received Entacapone-Placebo |
|
| Received Entacapone-Meth |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Baseline |
Baseline measurements were taking for each subject before drug intervention during each of the 4 visits then averaged over the 4 visits. Baseline measurements reported here are averaged across all subjects. |
| OG001 | Placebo Followed by Placebo | Subjects will receive placebo, then one hour later, placebo Placebo: capsules compounded to be of similar appearance to the active drugs |
| OG002 | Placebo Followed by Methamphetamine | Subjects will receive placebo, then one hour later, methamphetamine Methamphetamine: Methamphetamine 20 mg oral dose Placebo: capsules compounded to be of similar appearance to the active drugs |
| OG003 | Entacapone Followed by Placebo | Subjects will receive entacapone, then one hour later, placebo Entacapone: Entacapone 200 mg oral dose Placebo: capsules compounded to be of similar appearance to the active drugs |
| OG004 | Entacapone Followed by Methamphetamine | Subjects will receive entacapone, then one hour later, methamphetamine Entacapone: Entacapone 200 mg oral dose Methamphetamine: Methamphetamine 20 mg oral dose |
|
|
| Primary | Effect of Entacapone on Subjective Effects of Methamphetamine | The subjective effects of the study drug were evaluated with the Addiction Research Center Inventory (ARCI-49), a 49 item questionnaire consisting of true/false items. True items receive a score of 1 if answer is 'True', false items receive a score of 1 if answer is 'False'. No points are given when answer is opposite to scoring direction. There are 5 subscales: Morphine Benzedrine group scale to measure euphoria (range: 0-16 with higher numbers indicating more euphoria), A Lysergic Acid Diethylamide group scale to estimate dysphoria and agitation (range: 0-14 with higher scores indicating more dysphoria), a Pentobarbital Chlorpromazine Alcohol group scale to measure sedation (range: 0-15 with higher scores indicating more sedation), and a Benzedrine group scale and an Amphetamine Scale to assess stimulant effects (range: 0-13 and 0-11, respectively, with higher scores indicating higher stimulant effects) . | The analysis population includes only the 12 subjects that completed each arm, or intervention, of the study. | Posted | Mean | Standard Deviation | units on a scale | Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint. |
|
|
|
| Primary | Effect of Entacapone on Methamphetamine-induced Stimulation | The Global Rating of Stimulation is a 1-item question "I feel light-headed, restless, or speeded-up" in which the participant is asked to circle one answer on a scale from 0-4, 0 is 'normal', 1 is 'slightly', 2 is 'moderately', 3 is 'very much', and 4 is 'extremely'. Whichever number they circled is their reported score. A higher score is indicative of a greater stimulating effect. | The analysis population includes only the 12 subjects that completed each arm, or intervention, of the study. | Posted | Mean | Standard Deviation | units on a scale | Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint. |
|
|
|
| Secondary | Cognitive Function | Two computer tests were administered to measure how each medication intervention effects cognitive functioning. The tests administered included the Rapid Visual Information Processing Task (RVIPT), a 6 minute test of sustained attention in which participants are requested to detect target sequences of digits and the Digit Symbol Substitution Task (DSST), a 2 minute test of psychomotor speed and sustained attention consisting of digit-symbol pairs followed by a list of digits where the subject identifies the symbol that corresponds to each digit as fast as possible. The number of correct responses within the allowed time is measured. Higher scores on both tasks indicate better performance. | The analysis population includes only the 12 subjects that completed each arm, or intervention, of the study. | Posted | Mean | Standard Deviation | number of correct answers | Measurements acquired before drug ingestion (baseline) then hourly for 4 hours. The peak interaction effect of entacapone and methamphetamine occurs 1 hour after ingestion, therefore the reported values are from this timepoint. |
|
|
|
| 0 |
| 19 |
| 0 |
| 19 |
| 1 |
| 19 |
| EG001 | Placebo-Placebo | Subjects will receive placebo, then one hour later, placebo Placebo: capsules compounded to be of similar appearance to the active drugs | 0 | 13 | 0 | 13 | 0 | 13 |
| EG002 | Placebo-Meth | Subjects will receive placebo, then one hour later, methamphetamine Placebo: capsules compounded to be of similar appearance to the active drugs Methamphetamine: Methamphetamine 20 mg oral dose | 0 | 13 | 0 | 13 | 0 | 13 |
| EG003 | Entacapone-Placebo | Subjects will receive entacapone, then one hour later, placebo Placebo: capsules compounded to be of similar appearance to the active drugs Entacapone: Entacapone 200 mg oral dose | 0 | 12 | 0 | 12 | 0 | 12 |
| EG004 | Entacapone-Meth | Subjects will receive entacapone, then one hour later, methamphetamine Methamphetamine: Methamphetamine 20 mg oral dose Entacapone: Entacapone 200 mg oral dose | 0 | 13 | 0 | 13 | 0 | 13 |
|
Not provided
Not provided
| Organic Chemicals |
| Lysergic Acid Diethylamide |
|
| Pentobarbital Chlorpromazine Alcohol |
|
| Benzedrine |
|
| Amphetamine |
|
| Digital Symbol Substitution Task |
|